China's National Medical Products Administration accepted the drug marketing authorization application of Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) unit, Beijing Shengdi Pharmaceutical, for SHR-2004 injection, according to a Tuesday disclosure in a Shanghai bourse filing.
The drug is used to prevent venous thromboembolism in adult patients undergoing elective knee replacement surgery.